高级检索
当前位置: 首页 > 详情页

Mechanistic insights on cytotoxicity of KOLR, Cinnamomum pauciflorum Nees leaf derived active ingredient, by targeting signaling complexes of phosphodiesterase 3B and rap guanine nucleotide exchange factor 3

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Tongde Hosp Zhejiang Prov, Zhejiang Acad Tradit Chinese Med, Canc Inst Integrated Tradit Chinese & Western Med, Hangzhou 310012, Zhejiang, Peoples R China [2]Sichuan Normal Univ, Coll Life Sci, Chengdu 610101, Sichuan, Peoples R China [3]Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Clin Med Coll 2, Guang Zhou, Guangdong, Peoples R China [4]Peoples Liberat Army Joint Logist Support Force 9, Nursing Dept, Hangzhou, Zhejiang, Peoples R China [5]Yibin Univ, Key Lab Fermentat Resources & Applicat Univ Sichu, Yibin, Sichuan, Peoples R China
出处:
ISSN:

关键词: phosphodiesterase 3B protein signaling complexes rap guanine nucleotide exchange factor 3 signaling pathway therapeutic cancer target

摘要:
Protein signaling complexes play important roles in prevention of several cancer types and can be used for development of targeted therapy. The roles of signaling complexes of phosphodiesterase 3B (PDE3B) and Rap guanine nucleotide exchange factor 3 (RAPGEF3), which are two important enzymes of cyclic adenosine monophosphate (cAMP) metabolism, in cancer have not been fully explored. In the current study, a natural product Kaempferol-3-O-(3 '',4 ''-di-E-p-coumaroyl)-alpha-L-rhamnopyranoside designated as KOLR was extracted from Cinnamomum pauciflorum Nees leaves. KOLR exhibited higher cytotoxic effects against BxCP-3 pancreatic cancer cell line. In BxPC-3 cells, the KOLR could enhance the formation of RAPGEF 3/ PDE3B protein complex to inhibit the activation of Rap-1 and PI3K-AKT pathway, thereby promoting cell apoptosis and inhibiting cell metastasis. Mutation of RAPGEF3 G557A or low expression of PDE3B inactivated the binding action of KOLR resulting in KOLR resistance. The findings of this study show that PDE3B/RAPGEF3 complex is a potential therapeutic cancer target.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 药物化学 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药物化学 2 区 药学
JCR分区:
出版当年[2020]版:
Q1 CHEMISTRY, MEDICINAL Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Tongde Hosp Zhejiang Prov, Zhejiang Acad Tradit Chinese Med, Canc Inst Integrated Tradit Chinese & Western Med, Hangzhou 310012, Zhejiang, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Tongde Hosp Zhejiang Prov, Zhejiang Acad Tradit Chinese Med, Canc Inst Integrated Tradit Chinese & Western Med, Hangzhou 310012, Zhejiang, Peoples R China [2]Sichuan Normal Univ, Coll Life Sci, Chengdu 610101, Sichuan, Peoples R China [*1]Cancer Institute of Integrated tradition Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. [*2]College of Life Science, Sichuan Normal University, Chengdu, Sichuan, 610101, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号